All In Biotech

Drug Trial Radar · NCT01045421

Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies

Last checked: Nov 19, 2026Latest source record: Aug 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 273 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

273

Actual

Start

Feb 2010

Primary completion

May 2013

Study completion Apr 2014

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
Jan 11, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter study with a phase 1 dose escalation portion and a 2-stage, phase 2 portion, investigating MLN8237 (alisertib) in patients with advanced nonhematological malignancies.

Conditions

  • Advanced Nonhematological Malignancies
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Metastatic Breast Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Gastroesophageal Adenocarcinoma

Interventions

  • MLN8237 (Alisertib)Drug

    Phase 1: MLN8237 will be administered orally twice a day on a 7-day dosing schedule Phase 2: MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)Time frame: Phase 1: Cycle 1 Day 1 to Cycle 2 Day 21
  2. Phase 2: Percentage of Participants With Objective ResponseTime frame: Baseline until complete response or partial response, assessed every 2 cycles up to end of study (up to 50 cycles)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Houston, Texas

  • Site not named

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.